NGM Biopharmaceuticals, Inc.

NASDAQ:NGM

1.54 (USD) • At close April 4, 2024
Bedrijfsnaam NGM Biopharmaceuticals, Inc.
Symbool NGM
Munteenheid USD
Prijs 1.54
Beurswaarde 128,532,096
Dividendpercentage 0%
52-weken bereik 0.6 - 4.69
Industrie Biotechnology
Sector Healthcare
CEO Dr. David J. Woodhouse Ph.D.
Website https://www.ngmbio.com

An error occurred while fetching data.

Over NGM Biopharmaceuticals, Inc.

NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the

Vergelijkbare Aandelen

Agios Pharmaceuticals, Inc. logo

Agios Pharmaceuticals, Inc.

AGIO

47.38 USD

RadNet, Inc. logo

RadNet, Inc.

RDNT

69.64 USD

Outset Medical, Inc. logo

Outset Medical, Inc.

OM

0.594 USD

Adaptive Biotechnologies Corporation logo

Adaptive Biotechnologies Corporation

ADPT

4.78 USD

Innoviva, Inc. logo

Innoviva, Inc.

INVA

19.67 USD

SomaLogic, Inc. logo

SomaLogic, Inc.

SLGC

2.1 USD

Allogene Therapeutics, Inc. logo

Allogene Therapeutics, Inc.

ALLO

2.91 USD

Instil Bio, Inc. logo

Instil Bio, Inc.

TIL

58.75 USD

Celularity Inc. logo

Celularity Inc.

CELU

2.76 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)